Home
  >  
Section 70
  >  
Chapter 69,888

Good Outcomes in Babies with in Utero Bedaquiline Exposure

Marais, B.J.

Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America 72(7): 1169-1170

2021

ISSN/ISBN: 1537-6591
PMID: 32141498
DOI: 10.1093/cid/ciaa174
Accession: 069887640
Download citation:  
Text
  |  
BibTeX
  |  
RIS
The lymph node metastasis of colorectal cancer (LMN-CRC) seriously threatens the prognosis of patients. Chemotherapy, as the most common treatment, results in severe bone marrow suppression. 20(S)-ginsenoside Rh2 (SGRh2), a major effective constituent of ginseng, has demonstrated therapeutic effects on a variety of diseases, including some tumours. SGRh2 treatment had no effect on other organs. Therefore, ginsenosides are considered a safe and effective antineoplastic drug. However, the effects of SGRh2 on LMN-Crc remain unknown. The present study investigated the potential effect of SGRh2 on LMN-Crc in vitro and in vivo. SW480 and Co Lo205 cell lines were treated with SGRh2. SGRh2 dose-dependently decreased Crc cell proliferation by CCK-8, colony formation and Edu assays. The Transwell and scratch assays revealed that SGRh2 inhibits the migratory and invasive abilities of Crc cells in a dose-dependent manner. Furthermore, the results of Western blotting revealed that SGRh2 decreased the expression of matrix metalloproteinase (MMP)-2 and MMP9. In terms of the underlying mechanisms, SGRh2 regulates Crc metastasis by affecting epithelial-mesenchymal transition (EMT), which significantly up-regulated epithelial biomarkers (E-cadherin) and down-regulated mesenchymal biomarkers (N-cadherin and vimentin) and Emt transcriptional factors (Smad-3, Snail-1, and Twist-1). In vivo, SGRh2 significantly inhibited LMN-Crc without affecting other normal organs. Immunohistochemical results showed that SGRh2 treats LMN-Crc by regulating EMT. These results demonstrate that SGRh2 has therapeutic potential for LMN-CRC.

PDF emailed within 0-6 h: $19.90




Related References

Heffron, R.; Mugo, N.; Hong, T.; Celum, C.; Marzinke, M.A.; Ngure, K.; Asiimwe, S.; Katabira, E.; Bukusi, E.; Odoyo, J.; Tindimwebwa, E.; Bulya, N.; Baeten, J.M. 2018: Pregnancy outcomes and infant growth among babies with in utero exposure to tenofovir-based pre-exposure prophylaxis for HIV prevention Aids 2018
Heffron, R.; Mugo, N.; Hong, T.; Celum, C.; Marzinke, M.A.; Ngure, K.; Asiimwe, S.; Katabira, E.; Bukusi, E.A.; Odoyo, J.; Tindimwebwa, E.; Bulya, N.; Baeten, J.M. 2018: Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention Aids 32(12): 1707-1713
Coimbra, Joao Carlos; Pinto, Iraja Damiani; Wurdig, Norma Luiza; Do Carmo, Dermeval Aparecido 2010: Outcomes of Babies with Severe Rhesus Disease Following In-Utero Transfusions - a 10 Year Experience Pediatric Research 68: 594-595
Karmon, A.E.; Sullivan, D.Y. 2019: Good outcomes in small babies, and the elephant in the room Fertility and Sterility 111(5): 887
Suththanantha, J.; Hoh, Y.; Hadoura, A.; Eisenhurt, M.; Alford, C.; Shanmugalingam, S. 2014: G214(P) Reducing transfusion donor exposure in preterm babies: good communication is vital Archives of Disease in Childhood 99(Suppl 1): A202-A203
Koebnick, C.; Tartof, S.Y.; Sidell, M.A.; Rozema, E.; Chung, J.; Chiu, V.Y.; Taylor, Z.W.; Xiang, A.H.; Getahun, D. 2019: Effect of In-Utero Antibiotic Exposure on Childhood Outcomes: Methods and Baseline Data of the Fetal Antibiotic EXposure (FAX) Cohort Study Jmir Research Protocols 8(7): E12065
Bertoni, E.; Larti, A.; Rosso, G.; Zanazzi, M.; Di Maria, L.; Salvadori, M. 2011: Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients Journal of Nephrology 24(5): 613-618
Hatch, M.; Little, M.P.; Brenner, A.V.; Cahoon, E.K.; Tereshchenko, V.; Chaikovska, L.; Pasteur, I.; Likhtarov, I.; Bouville, A.; Shpak, V.; Bolshova, O.; Zamotayeva, G.; Grantz, K.; Sun, L.; Mabuchi, K.; Albert, P.; Tronko, M. 2017: Neonatal outcomes following exposure in utero to fallout from Chernobyl European Journal of Epidemiology 32(12): 1075-1088
Gawronski, K.M.; Prasad, M.R.; Backes, C.R.; Lehman, K.J.; Gardner, D.K.; Cordero, L. 2014: Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone Sage Open Medicine 2: 2050312114530282
Vafeiadi, M.; Agramunt, S.; Pedersen, M.; Besselink, H.; Chatzi, L.; Fthenou, E.; Fleming, S.; Hardie, L.J.; Wright, J.; Knudsen, L.E.; Nielsen, J.K.S.; Sunyer, J.; Carreras, R.; Brunborg, G.; Gutzkow, K.B.; Nygaard, U.C.; Løvik, M.; Kyrtopoulos, S.A.; Segerbäck, D.; Merlo, D.F.; Kleinjans, J.C.; Vrijheid, M.; Kogevinas, M. 2014: In utero exposure to compounds with dioxin-like activity and birth outcomes Epidemiology 25(2): 215-224
Passarelli, S.; Bromage, S.; Darling, A.M.; Wang, J.-S.; Aboud, S.; Mugusi, F.; Griffiths, J.K.; Fawzi, W. 2020: Aflatoxin exposure in utero and birth and growth outcomes in Tanzania Maternal and Child Nutrition 16(2): E12917
Dorélien, A. 2019: The Effects of in Utero Exposure to Influenza on Birth and Infant Outcomes in the US Population and Development Review 45(3): 489-523
Dusick, A.M.; Covert, R.F.; Schreiber, M.D.; Tebbett, I.R.; Moore, C.M.; Browne, S.P. 1992: Risk of adverse outcomes after cocaine exposure in a cohort of 323 very low birthweight babies Pediatric Research 31(4 Part 2): 201A
Auerbach, D.I.; Buerhaus, P.I.; Staiger, D.O. 2020: Implications of the Rapid Growth of the Nurse Practitioner Workforce in the US Health Affairs 39(2): 273-279
Gray, R.D. 2010: Neonatal growth outcomes and in utero exposure to antidepressants: biological or social? Australian and New Zealand Journal of Psychiatry 44(9): 864